Literature DB >> 16478780

Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle.

Cheryl A Collier1, Clinton R Bruce, Angela C Smith, Gary Lopaschuk, David J Dyck.   

Abstract

The present study examined the acute effects of metformin on fatty acid (FA) metabolism in oxidative soleus (SOL) and glycolytic epitrochlearis (EPT) rodent muscle. SOL and EPT were incubated for either 30 or 180 min in the absence or presence of 2 mM metformin and with or without insulin (10 mU/ml). Metformin did not alter basal FA metabolism but countered the effects of insulin on FA oxidation and incorporation into triacylglyerol (TAG). Specifically, metformin prevented the insulin-induced suppression of FA oxidation in SOL but did not alter FA incorporation into lipid pools. In contrast, in EPT metformin blunted the incorporation of FA into TAG when insulin was present but did not alter FA oxidation. In SOL, metformin resulted in a 50% increase in AMP-activated protein kinase alpha2 activity and prevented the insulin-induced increase in malonyl-CoA content. In both fiber types, basal and insulin-stimulated glucose oxidation were not significantly altered by metformin. All effects were similar regardless of whether they were measured after 30 or 180 min. Because increased muscle lipid storage and impaired FA oxidation have been associated with insulin resistance in this tissue, the ability of metformin to reverse these abnormalities in muscle FA metabolism may be a part of the mechanism by which metformin improves glucose clearance and insulin sensitivity. The present data also suggest that increased glucose clearance is not due to its enhanced subsequent oxidation. Additional studies are warranted to determine whether chronic metformin treatment has similar effects on muscle FA metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16478780     DOI: 10.1152/ajpendo.00272.2005

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  41 in total

1.  Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice.

Authors:  Joanne S Allard; Evelyn J Perez; Koji Fukui; Priscilla Carpenter; Donald K Ingram; Rafael de Cabo
Journal:  Behav Brain Res       Date:  2015-12-14       Impact factor: 3.332

2.  Hydroxypropylated distarch phosphate versus unmodified tapioca starch: fat oxidation and endurance in C57BL/6J mice.

Authors:  Satoshi Haramizu; Akira Shimotoyodome; Daisuke Fukuoka; Takatoshi Murase; Tadashi Hase
Journal:  Eur J Appl Physiol       Date:  2012-01-24       Impact factor: 3.078

3.  Metformin activates AMP kinase through inhibition of AMP deaminase.

Authors:  Jiangyong Ouyang; Rahulkumar A Parakhia; Raymond S Ochs
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

4.  Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity.

Authors:  Rebecca J Ford; Morgan D Fullerton; Stephen L Pinkosky; Emily A Day; John W Scott; Jonathan S Oakhill; Adam L Bujak; Brennan K Smith; Justin D Crane; Regje M Blümer; Katarina Marcinko; Bruce E Kemp; Hertzel C Gerstein; Gregory R Steinberg
Journal:  Biochem J       Date:  2015-05-15       Impact factor: 3.857

Review 5.  AMP-activated protein kinase signaling in metabolic regulation.

Authors:  Yun Chau Long; Juleen R Zierath
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

Review 6.  Metformin--mode of action and clinical implications for diabetes and cancer.

Authors:  Ida Pernicova; Márta Korbonits
Journal:  Nat Rev Endocrinol       Date:  2014-01-07       Impact factor: 43.330

7.  Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy.

Authors:  Chuanrui Ma; Wenwen Zhang; Xiaoxiao Yang; Ying Liu; Lipei Liu; Ke Feng; Xiaomeng Zhang; Shu Yang; Lei Sun; Miao Yu; Jie Yang; Xiaoju Li; Wenquan Hu; Robert Q Miao; Yan Zhu; Luyuan Li; Jihong Han; Yuanli Chen; Yajun Duan
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

Review 8.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

9.  Type 2 diabetes mellitus: a review of current trends.

Authors:  Abdulfatai B Olokoba; Olusegun A Obateru; Lateefat B Olokoba
Journal:  Oman Med J       Date:  2012-07

Review 10.  Metformin: A Hopeful Promise in Aging Research.

Authors:  Marta G Novelle; Ahmed Ali; Carlos Diéguez; Michel Bernier; Rafael de Cabo
Journal:  Cold Spring Harb Perspect Med       Date:  2016-03-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.